ESR1 and neoplasm: Consistent with preclinical [32] and clinical [33] studies showing that combining anti-ER therapies with novel anti-HER2 treatments delays resistance development, our in vivo experiments reveal that the HER2 inhibitor trastuzumab does not enhance the repressive effect of fulvestrant monotherapy on tumor growth.